Pfizer Inc. (BCBA:PFE)
Argentina · Delayed Price · Currency is ARS | Market Cap | 269.89T +33.1% |
| Revenue (ttm) | 93.90T -0.2% |
| Net Income | 6.39T -59.7% |
| EPS | 293.55 -59.9% |
| Shares Out | n/a |
| PE Ratio | 43.77 |
| Forward PE | 10.73 |
| Dividend | 440.76 (3.43%) |
| Ex-Dividend Date | Nov 6, 2026 |
| Volume | 39,350 |
| Open | 12,700 |
| Previous Close | 12,630 |
| Day's Range | 12,500 - 12,850 |
| 52-Week Range | 8,800 - 12,850 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer Slides: Q3 2026
Pfizer has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Pfizer Earnings release: Q3 2026
Pfizer released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Pfizer Prepared remarks: Q3 2026
Pfizer filed a regulatory document on November 3, 2026 disclosing important business information.
Pfizer Stock (PFE) Rises on Q3 Earnings Beat and Raised 2026 Sales Outlook
Pfizer shares ($PFE) edged higher in Tuesday’s pre-market session after the U.S. pharma giant beat Q3 earnings expectations and raised its 2026 sales forecast. The company now expects full-year sales…
Pfizer Raises Forecast on Momentum With New Products
Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.
Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates
Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.
Pfizer hikes full-year outlook, taps company veteran as new CFO
Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also announced that Cecile Gueg...
Pfizer reports Q3 adjusted EPS 87c consensus 73c
Reports Q3 revenue $16.6B, consensus $15.88B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing...
Pfizer raises FY26 adjusted EPS view to $2.95-$3.05 from $2.80-$3.00
FY26 consensus $2.96. Raises FY26 revenue view to $62B-$64B from $60.5B-$62.5B, consensus $62.23B.
Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
Pfizer raised its annual forecasts on Tuesday as strong demand for its cancer drugs and blockbuster blood thinner Eliquis helped the drugmaker post better-than-expected third-quarter results.
Pfizer names Cecile Guegan as CFO
Pfizer (PFE) announced that its Board of Directors has unanimously appointed Cecile Guegan as CFO and Executive Vice President, effective November 1, 2026. Cecile has served as interim CFO since…
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXE...
Pfizer Appoints Cecile Guegan as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effectiv...
Pfizer (PFE) Reports Q3 Earnings Tomorrow — Here’s Why Wall Street Remains Split
U.S. pharma giant Pfizer ($PFE) is set to release its third-quarter 2026 earnings tomorrow, November 3, before the market opens. Despite pressure on its COVID-19 business, Pfizer’s shares are up…
Looking for income? These dividend stocks have high yields that seem well supported.
Ford, Pfizer and Verizon are among 11 stocks that passed a screen of the S&P 500 for high dividend yields that are expected to be well covered by the companies' free cash flow.
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.
ManpowerGroup appoints Lidia Fonseca to board of directors
ManpowerGroup (MAN) announced the election of Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer (PFE), to its Board of Directors, effective November 1. ...
Pfizer says Phase 3 MagnetisMM-32 study met primary endpoint
Pfizer (PFE) announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior li...
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or ref...
Pfizer announces FDA expanded approval for TALZENNA plus XTANDI
Pfizer (PFE) announced that the U.S. Food and Drug Administration has expanded approval of TALZENNA in combination with XTANDI to the treatment of men with metastatic androgen pathway modulation-naive...
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalu...
FDA announces approval of Pfizer’s Talzenna combination for prostate cancer
The Food and Drug Administration said it approved Pfizer’s (PFE) Talzenna in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naive or -sensitive p...
Pfizer announces results across serotypes in Phase 2 study of 25vPnC
Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, 25vPnC, in infants. In the study,...
Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure
Pfizer ($PFE) is keeping its experimental lung cancer drug alive despite a failed clinical trial. New data showed that some patients treated with sigvotatug vedotin lived more than two months…
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine...